Biological Products, (No Diagnostic Substances)
Standard Industrial Classification: SIC 2836
Industry Insider Sentiment Analysis
The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-25 03:13 | 2026-02-23 | VIR | Vir Biotechnology, Inc. | Sabatini Brent | Officer | SELL | $7.45 | 1,829 | $13,631 | 71,043 |
| 2026-02-25 01:52 | 2026-02-20 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | BUY | $5.86 | 171,410 | $1,003,966 | 80,000 |
| 2026-02-25 00:13 | 2026-02-20 | TNYA | Tenaya Therapeutics, Inc. | COLUMN GROUP III GP, LP | 10% owner | SELL | $0.61 | 829,734 | $504,810 | 2,211,757 |
| 2026-02-24 03:14 | 2026-02-19 | KRYS | Krystal Biotech, Inc. | ROSSI DINO A | Director | OPT+S | $261.41 | 18,950 | $4,953,695 | 78,691 |
| 2026-02-24 02:50 | 2026-02-19 | EXEL | EXELIXIS, INC. | Aftab Dana | Officer | SELL | $44.35 | 29,873 | $1,324,868 | 664,024 |
| 2026-02-24 01:00 | 2026-02-20 | CGEM | Cullinan Therapeutics, Inc. | Fenton Mary Kay | Officer | SELL | $13.62 | 4,398 | $59,901 | 126,380 |
| 2026-02-24 01:00 | 2026-02-20 | CGEM | Cullinan Therapeutics, Inc. | AHMED NADIM | Director, Officer | SELL | $13.62 | 16,381 | $223,109 | 404,318 |
| 2026-02-24 01:00 | 2026-02-20 | CGEM | Cullinan Therapeutics, Inc. | SUMER JACQUELYN L | Officer | SELL | $13.62 | 3,742 | $50,966 | 131,690 |
| 2026-02-24 01:00 | 2026-02-20 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Officer | OPT+S | $14.08 | 11,742 | $165,366 | 181,977 |
| 2026-02-24 01:00 | 2026-02-20 | CGEM | Cullinan Therapeutics, Inc. | Jones Jeffrey Alan | Officer | SELL | $13.62 | 4,982 | $67,855 | 164,550 |
| 2026-02-21 01:05 | 2026-02-18 | LXEO | Lexeo Therapeutics, Inc. | Otero Jose Manuel | Officer | SELL | $6.40 | 3,016 | $19,294 | 125,460 |
| 2026-02-21 01:05 | 2026-02-18 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | Director, Officer | SELL | $6.38 | 10,173 | $64,924 | 392,483 |
| 2026-02-21 01:05 | 2025-11-18 | LXEO | Lexeo Therapeutics, Inc. | Otero Jose Manuel | Officer | SELL | $9.27 | 721 | $6,684 | 63,476 |
| 2026-02-21 00:04 | 2026-02-18 | VYGR | Voyager Therapeutics, Inc. | Swartz Robin | Officer | SELL | $3.44 | 3,882 | $13,354 | 206,196 |
| 2026-02-21 00:03 | 2026-02-18 | VYGR | Voyager Therapeutics, Inc. | Carter Todd Alfred | Officer | SELL | $3.44 | 3,301 | $11,355 | 149,892 |
| 2026-02-21 04:36 | 2026-02-18 | EXEL | EXELIXIS, INC. | WYSZOMIERSKI JACK L | Director | OPT+S | $44.01 | 99,574 | $4,382,252 | 279,942 |
| 2026-02-21 03:43 | 2026-02-19 | AMGN | Amgen Inc. | Busch Matthew C. | Officer | SELL | $375.79 | 1,000 | $375,790 | 3,423 |
| 2026-02-21 01:35 | 2026-02-19 | CRSP | CRISPR Therapeutics AG | KASINGER JAMES R. | Officer | OPT+S | $52.58 | 2,112 | $111,049 | 85,115 |
| 2026-02-21 01:36 | 2026-02-19 | CRSP | CRISPR Therapeutics AG | Kulkarni Samarth | Director, Officer | OPT+S | $52.58 | 6,967 | $366,325 | 226,106 |
| 2026-02-21 01:30 | 2026-02-20 | KYMR | Kymera Therapeutics, Inc. | Esposito Pamela | Director | OPT+S | $87.31 | 2,500 | $218,270 | 0 |
| 2026-02-21 00:01 | 2026-02-18 | VYGR | Voyager Therapeutics, Inc. | Sandrock Alfred | Director, Officer | SELL | $3.41 | 11,732 | $40,006 | 498,257 |
| 2026-02-20 01:04 | 2026-02-17 | NMRA | Neumora Therapeutics, Inc. | Milligan Michael Lee | Officer | SELL | $3.57 | 1,436 | $5,119 | 21,034 |
| 2026-02-20 00:05 | 2026-02-17 | TWST | Twist Bioscience Corp | Green Paula | Officer | SELL | $52.40 | 39,404 | $2,064,770 | 126,041 |
| 2026-02-20 00:05 | 2026-02-17 | TWST | Twist Bioscience Corp | Finn Patrick John | Officer | OPT+S | $51.65 | 68,967 | $3,562,415 | 287,788 |
| 2026-02-20 01:05 | 2026-02-17 | NMRA | Neumora Therapeutics, Inc. | BERNS PAUL L | Director, Officer | SELL | $3.51 | 9,819 | $34,459 | 7,395,185 |
| 2026-02-20 03:18 | 2026-02-17 | EXEL | EXELIXIS, INC. | Smith Julie | Director | OPT+S | $44.00 | 106,539 | $4,687,343 | 20,590 |
| 2026-02-20 03:30 | 2026-02-18 | RXRX | RECURSION PHARMACEUTICALS, INC. | Taylor Ben R | Officer | SELL | $3.08 | 13,426 | $41,352 | 1,195,349 |
| 2026-02-20 03:30 | 2026-02-19 | RXRX | RECURSION PHARMACEUTICALS, INC. | Gibson Christopher | Director | SELL | $3.46 | 40,000 | $138,400 | 906,556 |
| 2026-02-20 02:26 | 2026-02-19 | ACLX | Arcellx, Inc. | Gilson Michelle | Officer | OPT+S | $68.29 | 8,384 | $572,568 | 45,157 |
| 2026-02-20 01:06 | 2026-02-17 | NMRA | Neumora Therapeutics, Inc. | Pinto Joshua | Officer | SELL | $3.54 | 5,967 | $21,093 | 57,783 |
| 2026-02-20 01:07 | 2026-02-17 | NMRA | Neumora Therapeutics, Inc. | Aurora Daljit Singh | Officer | SELL | $3.56 | 6,165 | $21,917 | 82,770 |
| 2026-02-20 00:57 | 2026-02-17 | TECH | BIO-TECHNE Corp | Herr Amy E. | Director | SELL | $59.11 | 1,976 | $116,791 | 200 |
| 2026-02-20 01:00 | 2026-02-18 | IMCR | Immunocore Holdings plc | Berman David M | Officer | OPT+S | $32.35 | 5,965 | $192,968 | 5,859 |
| 2026-02-20 01:00 | 2026-02-18 | IMCR | Immunocore Holdings plc | St Leger Tina Amber | Officer | OPT+S | $32.35 | 1,000 | $32,350 | 1,119 |
| 2026-02-20 01:00 | 2026-02-18 | IMCR | Immunocore Holdings plc | GOLL JOHN | Officer | OPT+S | $32.35 | 698 | $22,580 | 653 |
| 2026-02-20 01:00 | 2026-02-18 | IMCR | Immunocore Holdings plc | Jallal Bahija | Director, Officer | OPT+S | $32.35 | 11,474 | $371,184 | 12,343 |
| 2026-02-20 00:30 | 2026-02-17 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | Officer | SELL | $46.53 | 7,989 | $371,714 | 106,929 |
| 2026-02-20 00:30 | 2026-02-17 | SRRK | Scholar Rock Holding Corp | Parlavecchio Caryn | Officer | SELL | $46.53 | 9,035 | $420,382 | 169,087 |
| 2026-02-20 00:30 | 2026-02-17 | SRRK | Scholar Rock Holding Corp | Ho Junlin | Officer | SELL | $46.53 | 9,580 | $445,740 | 241,545 |
| 2026-02-20 00:30 | 2026-02-17 | SRRK | Scholar Rock Holding Corp | Marantz Jing L. | Officer | SELL | $46.53 | 4,157 | $193,418 | 126,012 |
| 2026-02-20 00:30 | 2026-02-18 | DTIL | PRECISION BIOSCIENCES INC | SMITH J. JEFFERSON | Officer | OPT+S | $3.84 | 4,925 | $18,912 | 121,926 |
| 2026-02-20 00:30 | 2026-02-18 | DTIL | PRECISION BIOSCIENCES INC | Scimeca Dario | Officer | OPT+S | $3.84 | 4,925 | $18,912 | 56,457 |
| 2026-02-20 00:31 | 2026-02-18 | DTIL | PRECISION BIOSCIENCES INC | Kelly John Alexander | Officer | OPT+S | $3.84 | 8,149 | $31,292 | 125,883 |
| 2026-02-20 00:31 | 2026-02-18 | DTIL | PRECISION BIOSCIENCES INC | Amoroso Michael | Director, Officer | OPT+S | $3.84 | 20,559 | $78,947 | 243,392 |
| 2026-02-19 01:19 | 2026-02-17 | ACLX | Arcellx, Inc. | Gilson Michelle | Officer | OPT+S | $69.51 | 11,291 | $784,782 | 53,541 |
| 2026-02-19 01:22 | 2026-02-17 | GILD | GILEAD SCIENCES, INC. | Mercier Johanna | Officer | OPT+S | $154.44 | 28,000 | $4,324,228 | 120,288 |
| 2026-02-19 00:05 | 2026-02-13 | TWST | Twist Bioscience Corp | CHESS ROBERT | Director | SELL | $48.26 | 2,184 | $105,402 | 21,084 |
| 2026-02-19 05:34 | 2026-02-18 | SLDB | Solid Biosciences Inc. | Hanrahan Jessie | Officer | OPT+S | $5.82 | 4,134 | $24,074 | 74,318 |
| 2026-02-19 05:38 | 2026-02-18 | SLDB | Solid Biosciences Inc. | Cumbo Alexander | Director, Officer | OPT+S | $5.82 | 16,644 | $96,923 | 235,405 |
| 2026-02-19 05:25 | 2026-02-18 | SLDB | Solid Biosciences Inc. | Tan Kevin | Officer | OPT+S | $5.82 | 5,404 | $31,469 | 99,422 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Biological Products, (No Diagnostic Substances)
Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.